Google
CRDL — CARDIOL THERAPEUTICS INC CLASS A (Healthcare >> Drug Manufacturers - Specialty & Generic)
CRDL FAQ
What is CRDL's ROE?
CARDIOL THERAPEUTICS INC CLASS A reports a Return on Equity (ROE) of -149.91%.
What is CRDL's dividend yield?
CARDIOL THERAPEUTICS INC CLASS A offers a dividend yield of 0.00%.
What is CRDL's Deepscope Quality Score?
Deepscope rates CRDL's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy CRDL?
Deepscope's AI Timing Score for CRDL is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does CRDL belong to?
CARDIOL THERAPEUTICS INC CLASS A is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NASDAQ exchange.
|
USD 1.11
Price
-0.04
(-3.48%)
Day Change
|
|
|---|
CRDL, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 97 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.11 |
| PBV / Sector |
5.37 / 2.76
|
| Earning Per Share | -0.31 |
| PE / Sector |
N/A / 23.64
|
| PEG or PE/Growth / Sector |
N/A / 0.13
|
| Average 1M Daily Value |
0.50 M
GREAT
|
| Average 1W Daily Value |
0.58 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
37% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:08:21 |
| Symbol | CRDL |
| Name | CARDIOL THERAPEUTICS INC CLASS A |
| Sector | Healthcare >> Drug Manufacturers - Specialty & Generic |
| Market | NASDAQ |
| Listed Shares | 115.27 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 130.26 / 9,835.56 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 2265 Upper Middle Road East, Oakville, ON, Canada, L6H 0G5
Phone: 289 910 0850
Website: https://www.cardiolrx.com
Sector: Healthcare >> Drug Manufacturers - Specialty & Generic
Description: Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
ME vs SECTOR Healthcare >> Drug Manufacturers - Specialty & Generic
Click a bubble to view stock details · Bubble size represents market capitalization share
